The Virus Filtration Market report evaluates the important characteristics of the Virus Filtration market based on present industry scenarios, market demands and business strategies. The Market report separates the Virus Filtration industry based on the Types, Applications, Key Players & Regions.
Market OverviewThe Global Virus Filtration market is projected to grow at a CAGR of approximately 12% during the forecast period (2018–2023). The global Virus Filtration market is experiencing considerable growth due to factors like increasing R&D spending, growth in biopharmaceutical industry, and increasing government support for the pharmaceutical and biotechnology industry.Growth in Biopharmaceutical IndustryAccording to Mordor Intelligence estimates, the global biopharmaceuticals market is estimated to reach USD 341.16 billion in 2023. Biotechnology derived medicinal products are presently the best characterized biologicals with considerable production and clinical experience, and have revolutionized the treatment of some of the most difficult-to-treat diseases, prolonging and improving the quality of life and patient care. Opportunities in biopharmaceuticals have been constantly increasing over the past decade. The efficacy and the safety of the drugs are some of the key product features that drive the marketâs growth. There have been biopharmaceutical products that are improving the quality of life and reducing the death rates in patients with HIV/AIDs, cancer, cystic fibrosis, and rheumatoid arthritis. Biopharmaceuticals have reduced the number of deaths caused due to cancer and HIV/AIDS in the last decade. The efficacy of the drugs and their safety has increased the acceptance for biopharmaceuticals. This growth in biopharmaceutical industry has spurred the growth of virus filtration market. Virus filtration technologies are both directly and indirectly exploited in biopharmaceutical industry.Stringent Regulations for Validation of Filtration ProductsSome biological therapeutic products are produced using mammalian cell lines or human plasma. The risk of contamination with either known or unknown viruses in these products has been demonstrated; hence, regulatory agencies have mandated that manufacturers evaluate the risks of virus contamination and take necessary measures to mitigate these risks. In addition to ensuring the purity of source materials, manufacturers are encouraged to institute steps in the purification process that will clear endogenous and adventitious viruses. Filtration has been successfully used in numerous processes as a robust step for virus clearance. Regulators require that an overall safety margin, such as <1 virus particle per 10^6 doses, be used to demonstrate the virus safety of the manufacturing process. The drug manufacturer is required to quantify the virus "load" in the process. For biotech products derived from murine cell lines such as Chinese hamster ovaries (CHO) and non-sense oligonucleotide (NSO), this typically translates to ~12â18 log10 clearance for endogenous retroviruses and ~6 log10 removal for adventitious viruses. The US Food and Drug Administration (FDA) requires that manufacturers of biotech products that use murine cell lines are to demonstrate the clearance capability of their manufacturing processes with one relevant retrovirus (murine retrovirus) before starting Phase I studies. Regulatory agencies in Germany and France require that manufacturing processes be evaluated to clear non-enveloped parvoviruses in addition to retroviruses. Before marketing authorization, manufacturers are required to assess clearance of multiple model and relevant viruses in their manufacturing processes. Overall, the stringent nature of the regulations for virus filtration is a major deterrent to the growth of the global virus filtration market.North America has the Largest Share in Global Virus Filtration Market The global Virus Filtration market has been segmented into five major Regions, viz. North America, Europe, Asia Pacific, Middle East & Africa, and South America. Driven by the developed country of the U.S., North America dominated the global Virus Filtration market In 2017, due to factors such as increasing R&D activities in biopharmaceutical industry, growth of chronic illnesses, and also due increasing government interest in reducing burden of infections.
Ask for Sample Copy of Report @ https://www.industryresearch.biz/enquiry/request-sample/13104509
Virus Filtration market report provides the comprehensive analysis of the market, based on leading players of present, past of Virus Filtration Industry and resourceful data that will act as a supportive guide for leading players.
Major Key Players of Virus Filtration Market Report: Asahi Kasei Medical Co. Ltd., Charles River Laboratories International Inc., General Electric Company, Lonza Group Ltd., Merck KgaA, Pall Corporation, Sartorius AG, Sigma-Aldrich Corporation, Thermo Fischer Scientific Inc., and Wuxi Pharmatech (Cayman) Inc. .
Key Stakeholders in Virus Filtration Market Report:
- Virus Filtration Manufacturers
- Virus Filtration Distributors/Traders/Wholesalers
- Virus Filtration Subcomponent Manufacturers
- Industry Association
- Downstream Vendors
Reasons to Purchase this Report:
Price of Report: $ 4250 (Single User License)
Purchase Report @ https://www.industryresearch.biz/purchase/13104509
In a word, the Virus Filtration Market report provides major statistics on the state of the Virus Filtration industry and is a valuable source of guidance and direction for companies and individuals interested in the market.